|
CDKN2B-AS1
|
0.170 |
GeneticVariation
|
disease |
BEFREE |
This case-control study evaluated the association between the rs2151280 in lncRNA CDKN2B-AS1 and lung cancer risk.
|
31775885 |
2019 |
|
CDKN2B-AS1
|
0.170 |
AlteredExpression
|
disease |
BEFREE |
The results suggest the expression of the CDKN2B-AS1 and adjacent gene, CDKN2A, are downregulated in the peripheral blood of patients with IPF, which activates the p53-signaling pathway to promote lung cancer formation.
|
29541247 |
2018 |
|
CDKN2B-AS1
|
0.170 |
GeneticVariation
|
disease |
GWASCAT |
Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes.
|
28604730 |
2017 |
|
CDKN2B-AS1
|
0.170 |
Biomarker
|
disease |
BEFREE |
In conclusion, ANRIL and MEG3 genetic polymorphisms are associated with severe platinum toxicity and could be considered as biomarkers for pretreatment evaluation in Chinese patients with lung cancer.
|
28260796 |
2017 |
|
CDKN2B-AS1
|
0.170 |
GeneticVariation
|
disease |
GWASCAT |
Cross-Cancer Genome-Wide Analysis of Lung, Ovary, Breast, Prostate, and Colorectal Cancer Reveals Novel Pleiotropic Associations.
|
27197191 |
2016 |
|
CDKN2B-AS1
|
0.170 |
GeneticVariation
|
disease |
BEFREE |
HOTTIP, CCAT2, H19, HOTAIR, MALATI, ANRIL genetic polymorphisms were significantly associated with lung cancer susceptibility or platinum-based chemotherapy response.
|
26729200 |
2016 |
|
CDKN2B-AS1
|
0.170 |
AlteredExpression
|
disease |
BEFREE |
The expression level of lncRNA ANRIL was higher in NSCLC tissues and lung cancer cells than in adjacent non-tumor tissues and normal human bronchial epithelial cells.
|
25889788 |
2015 |
|
CDKN2B-AS1
|
0.170 |
Biomarker
|
disease |
BEFREE |
ANRIL, a lncRNA co-clustered mainly with p14/ARF has been reported to be dysregulated in gastric cancer, esophageal squamous cell carcinoma, and lung cancer.
|
25966845 |
2015 |
|
CDKN2B-AS1
|
0.170 |
Biomarker
|
disease |
BEFREE |
Collectively, our findings showed that ANRIL is an lncRNA responsible in anti-tumorigenesis caused by PLD inhibition and combined incorporation of ANRIL into PLD inhibition-induced anti-tumorigenic signaling network could be a new effective therapeutic approach for controlling lung cancer.
|
25964559 |
2015 |